UBS Group’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-4,084
Closed -$87.7K 10480
2024
Q1
$87.7K Buy
4,084
+4,042
+9,624% +$26.8K ﹤0.01% 6282
2023
Q4
$154 Buy
42
+5
+14% +$20 ﹤0.01% 8861
2023
Q3
$144 Hold
37
﹤0.01% 8797
2023
Q2
$156 Sell
37
-591
-94% -$1.87K ﹤0.01% 8440
2023
Q1
$1.87K Buy
628
+590
+1,553% +$2.18K ﹤0.01% 8630
2022
Q4
$188 Buy
+38
New +$145 ﹤0.01% 10327
2022
Q3
Sell
-124
Closed -$1K 11408
2022
Q2
$1K Buy
+124
New +$1.13K ﹤0.01% 10112
2022
Q1
Sell
-381
Closed -$18K 11278
2021
Q4
$18K Buy
+381
New +$40K ﹤0.01% 8023
2021
Q2
Sell
-183
Closed -$18K 10043
2021
Q1
$18K Buy
+183
New +$23.9K ﹤0.01% 7489

UBS Group's LABP Position: Q2 2024 in Review

UBS Group sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q2 2024, closing a stake of 4,084 shares — an estimated $87.7K sold.

UBS Group first reported a position in LABP in Q1 2021 and held it in 9 quarters. The position peaked at $87.7K in Q1 2024. 0 funds tracked by Wall St. Rank hold LABP as of Q2 2024.

  • UBS Group reported no remaining Landos Biopharma, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • UBS Group sold 4,084 Landos Biopharma, Inc. Common Stock shares in Q2 2024, an estimated $87.7K.
  • UBS Group first reported a position in Landos Biopharma, Inc. Common Stock in Q1 2021 and held it in 9 quarters.
  • UBS Group's Landos Biopharma, Inc. Common Stock position peaked at $87.7K in Q1 2024.
  • 0 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q2 2024.

Based on UBS Group's 13F filing for Q2 2024, filed 14 Aug 2024.